Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine,tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,raxtozinameran, Date of authorisation: 21/12/2020, Revision: 54, Status: Authorised

30 June 2025

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 55, Status: Authorised

30 June 2025

Transparency: exceptional measures for COVID-19 medicines

30 June 2025

Human medicines European public assessment report (EPAR): Jardiance, empagliflozin, Date of authorisation: 22/05/2014, Revision: 32, Status: Authorised

30 June 2025

Orphan designation: Humanised IgG1 monoclonal antibody against human epidermal growth factor receptor 2 Treatment of gastric cancer, 22/05/2025 Positive

30 June 2025

Human medicines European public assessment report (EPAR): BroPair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised

30 June 2025

Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Date of authorisation: 03/10/2011, Revision: 20, Status: Authorised

30 June 2025

Orphan designation: Taladegib Treatment of idiopathic pulmonary fibrosis, 22/05/2025 Positive

30 June 2025

Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Date of authorisation: 11/11/2016, Revision: 21, Status: Authorised

30 June 2025

Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Date of authorisation: 29/09/2000, Revision: 56, Status: Authorised

30 June 2025